Abstract |
Missile therapy, which destroys cancer cells specifically, has been advocated as an effective modality for the treatment of carcinoma. We have developed an immunoconjugate consisting of the monoclonal antibody MSN-1 ( IgM), which reacts strongly with endometrial adenocarcinomas, combined with a plant hemitoxin named gelonin via a disulfide bond using N-succinimidyl-3-(2-pyridyldithio) propionate and 2-iminothiolane, and examined its selective cytotoxicity in athymic mice. The reductions in resected weights of target tumor cells, at the local site of MSN-1-gelonin immunoconjugate treatment, were 96% with local administration and 75% with caudal vein administration, as compared with the untreated group. There was no weight loss in treated mice. Our results suggest that this MSN-1-gelonin immunoconjugate has potential clinical applications in the treatment of endometrial adenocarcinomas.
|
Authors | Y Kaneta, K Tsukazaki, K Kubushiro, R Aoki, M Sakayori, M Ueda, S Nozawa |
Journal | Japanese journal of cancer research : Gann
(Jpn J Cancer Res)
Vol. 89
Issue 5
Pg. 583-8
(May 1998)
ISSN: 0910-5050 [Print] Japan |
PMID | 9685864
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents, Phytogenic
- Immunoconjugates
- Plant Proteins
- Ribosome Inactivating Proteins, Type 1
- GEL protein, Gelonium multiflorum
|
Topics |
- Adenocarcinoma
(therapy)
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Agents, Phytogenic
(therapeutic use)
- Cell Death
- Endometrial Neoplasms
(therapy)
- Female
- Immunoconjugates
(therapeutic use)
- Mice
- Mice, Nude
- Organ Size
- Plant Proteins
(administration & dosage, therapeutic use)
- Ribosome Inactivating Proteins, Type 1
- Tumor Cells, Cultured
|